Shares of CIRC (01763) rose more than 5% during the afternoon trading session. At the time of writing, the stock was up 4.71% to HK$18.02, with a turnover of HK$1.2164 million.
The increase follows a company announcement regarding a recent development. A subsidiary of CIRC, Chengdu CNNC High-Tech Isotope Co., Ltd., has completed construction of the second phase of its Radiological Source Research, Development, and Production Base project. This phase has successfully obtained an additional permit under its radiation safety license.
This approval allows for the official commencement of production on several new radiological source lines, including Californium-252, Caesium-137, and Americium-241. The full operation of these new lines is designed to comprehensively meet diverse market demands.
The complete launch of this project signifies an acceleration in technological upgrades and the transition between old and new production capacities within China's sealed radiological source sector. It further solidifies the country's leading position in the research, development, and industrial application of radiological sources.
The first phase of the Radiological Source R&D and Production Base project received its radiation safety license in August 2025. The recent approval for the second phase marks the full completion and operational launch of what is now Asia's largest facility of its kind.
The base now houses 14 production lines for various radiological sources, such as Carbon-14 and Krypton-85 sources. It has the capability to produce high-quality radiological source products containing over 70 different nuclides.
With an annual production capacity expected to exceed 100,000 sources, the base is positioned to fulfill current domestic demand across multiple sectors including industry, agriculture, medicine, national defense, and aerospace.
Comments